Author of

• 25936

  +

  P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26773

    +

    P1.16-63 - The Value of Adjuvant Chemotherapy in Patients with Resected Stage IB Solid Predominant and Solid Non-Predominant Lung Adenocarcinoma (ID 12269)

    16:45 - 18:00  |  Presenting Author(s): Shuhui Cao
    • Abstract
    • Slides

    Background
    

    The adjuvant chemotherapy(ACT) of stage IB lung adenocarcinoma remain controversial. We are intended to explore the benefits adjuvant chemotherapy made on patients in IB with solid ingredients.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A number of 334 completely resected patients with lung adenocarcinoma in stage IB from 2006 to 2015 were reviewed. All the pathological slides were evaluated with solid ingredients composed.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Our data showed that although disease-free survival (DFS)(p=0.661) and overall survival (OS)(p=0.130) were not significantly different in solid growth pattern with or without ACT, patients with solid predominant patterns tend to have longer DFS [hazard ratio (HR) 0.403, p=0.021)]and OS (HR 0.286, p=0.009) with ACT. In patients with solid non-predominant patterns, receiving ACT had no influence in DFS(p=0.231) and OS (p=0.611).

    

    

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    The solid predominant pattern in postoperative patients of stage IB could benefit from adjuvant, and solid non-predominant pattern couldn’t.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.